<DOC>
	<DOCNO>NCT00062283</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy alanosine use different way stop tumor cell divide stop grow die . PURPOSE : This phase II trial study well alanosine work treat patient soft tissue sarcoma , sarcoma bone , mesothelioma , non-small cell lung cancer , pancreatic cancer .</brief_summary>
	<brief_title>Alanosine Treating Patients With Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient methylthioadenosine phosphorylase ( MTAP ) -deficient cancer treat alanosine . - Determine time response duration response patient treated drug . - Determine progression-free survival patient treated drug . - Determine pharmacodynamic activity drug patient , base special imaging measure tumor adenosine triphosphate depletion . - Determine pharmacokinetic activity drug patient . - Determine safety tolerability drug patient . OUTLINE : This nonrandomized , open-label , multicenter study . Patients receive alanosine IV continuously day 1-5 . Treatment repeat every 21 day 9 course absence disease progression unacceptable toxicity . Patients follow 28 day . PROJECTED ACCRUAL : A total 50-145 patient ( 10-29 per tumor type ) accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Alanosine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm malignancy follow type : Softtissue sarcoma High grade Chemotherapy naïve progressive metastatic 2 prior cytotoxic treatment regimen ( include adjuvant therapy ) Sarcoma bone ( include osteosarcoma* chondrosarcoma ) High grade Progressive recurrent 2 prior cytotoxic treatment regimens No newly diagnose chemotherapy naïve disease NOTE : *Prior treatment cisplatin doxorubicin require Mesothelioma Unresectable Chemotherapy naïve progressive 1 prior cytotoxic chemotherapy regimen Not amenable curative treatment surgery Evidence gross unresectability include , limited , direct extension chest wall , mediastinal hilar lymphadenopathy , pulmonary cardiac function inadequate tolerate resection , sarcomatoid mixed histology Nonsmall cell lung cancer Stage III malignant pleural pericardial effusion , stage IV , progressive 2 prior cytotoxic chemotherapy regimens No newly diagnose chemotherapy naïve disease Pancreatic cancer Stage IV adenocarcinoma 1 prior cytotoxic treatment regimen No newly diagnose chemotherapy naïve disease No Ewing 's sarcoma soft tissue bone Documented absence methylthioadenosine phosphorylase fix tumor specimens Measurable disease For tumor type , least 1 lesion measurable MRI CT scan Chest xray allow clearly define lesion surround aerated lung Soft tissue component bone disease consider measurable provide measure MRI CT scan Must outside previously irradiate area No uncontrolled CNS metastasis primary tumor study Patients brain metastasis eligible brain metastasis treat prior radiotherapy and/or surgery , neurologically stable progressing symptom , steroid anticonvulsant PATIENT CHARACTERISTICS : Age 18 ( 13 osteosarcoma ) Performance status WHO 02 Life expectancy At least 3 month Hematopoietic Absolute granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) Alkaline phosphatase great 2.5 time ULN AST ALT great 2.5 time ULN ( 5 time ULN liver metastasis present ) Renal Creatinine great 1.5 time ULN Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 4 week study treatment No premalignant bony lesion ( e.g. , Paget 's disease ) No concurrent active malignancy except completely excise nonmelanoma skin cancer carcinoma situ cervix bladder No serious infection No medical psychiatric condition would preclude achievement study objective PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics More 42 day since prior nitrosoureas mitomycin Endocrine therapy See Disease Characteristics Radiotherapy See Disease Characteristics At least 28 day since prior brain radiotherapy More 28 day since prior radiotherapy 50 % bone marrow Surgery See Disease Characteristics At least 28 day since prior thoracic major surgery Other Recovered prior therapy More 28 day since prior cytotoxic agent More 28 day since prior anticancer investigational agent No concurrent antitumor treatment</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>advanced malignant mesothelioma</keyword>
	<keyword>recurrent malignant mesothelioma</keyword>
	<keyword>metastatic osteosarcoma</keyword>
	<keyword>recurrent osteosarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
	<keyword>chondrosarcoma</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>stage II adult soft tissue sarcoma</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>